TOP > 外国特許検索 > POLYPEPTIDE FOR FORSTER RESONANCE ENERGY TRANSFER

POLYPEPTIDE FOR FORSTER RESONANCE ENERGY TRANSFER

Foreign code F150008257
Posted date 2015年3月27日
Country 世界知的所有権機関(WIPO)
International application number 2014JP060185
International publication number WO 2014168143
Date of international filing 平成26年4月8日(2014.4.8)
Date of international publication 平成26年10月16日(2014.10.16)
Priority data
  • 特願2013-080738 (2013.4.8) JP
Title POLYPEPTIDE FOR FORSTER RESONANCE ENERGY TRANSFER
Abstract The purpose of the present invention is to provide a method for measuring the activity of a tyrosine kinase with high efficiency while reducing the number of cells which cannot be evaluated with respect to FRET. The problem can be solved by a polypeptide which is selected from polypeptides (1) and (2) as mentioned below and to which a donor and an acceptor for inducing Forster resonance energy transfer are bound: (1) a polypeptide which comprises an amino acid sequence that has the substitution of at least one amino acid residue selected from amino acid residues lying between position-91 to position-97 and/or at least one amino acid residue selected from amino acid residues lying between position-201 to position-222 in the amino acid sequence represented by SEQ ID NO: 2; and (2) a polypeptide which comprises an amino acid sequence that has the deletion of 1st to 81st amino acid residues as numbered from the carboxyl terminal side and also has the substitution of at least one amino acid residue selected from amino acid residues lying between position-91 to position-97 and/or at least one amino acid residue selected from amino acid residues lying between position-201 to position-222 in the amino acid sequence represented by SEQ ID NO: 2.
Outline of related art and contending technology BACKGROUND ART
Leukemia, standing and serious complications leading to death by blood tumor disorder. Which is a kind of leukemia chronic myelogenous leukemia (CML) acute lymphoblastic leukemia (ALL) and a part of in, 9, 22 caused by the reciprocal translocation chromosome characteristic Philadelphia (Ph1) bcr-abl chromosomal translocation is formed by the fusion gene, the constitutive tyrosine kinase activity from this gene (BCR-ABL) cytoplasmic proteins can be expressed, this BCR-ABL tyrosine kinase activity of phosphorylated by a variety of proteins can be associated with the onset, and the like are known.
As a method for the treatment of leukemia, in general, such as anti-cancer treatment or hematopoietic stem cell transplantation by administering a pharmaceutically transplantation treatment of either, or both is selected. In particular, pharmaceutical treatment CML, 2 - phenylaminopyrimidine tyrosine kinase inhibitor-based compounds and made about the administration, at present, 'imatinib' is a registered trademark of (imatinib, STI-571 or registered trademark name Gleevec also referred to as) the administration of the standard pharmaceutical therapy at present.
Imatinib, BCR-ABL ATP in the kinase domain binding site of the target, a high selectivity of a molecular target which is a kind of the drug. In general, the use of a molecular target drug, and the specificity of the effect expected from the high safety, which is one of the ideal therapy. But at the same time, the use of molecular target drugs, to patients with a mutation in a target molecule exhibits the desired therapeutic effect is expected with a problem that it is difficult in many cases, typified by BCR-ABL Imatinib and a targeting molecule-based compounds such as phenylaminopyrimidine tyrosine kinase inhibitor 2 - more or not.
Therefore, by BCR-ABL kinase domain mutations, such as imatinib (tyrosine kinase inhibitor) patient effect cannot be obtained in order to find, important to examine drug resistance. Conventional, inspection of imatinib resistance in a patient, mainly, bcr-abl gene of the patient and determine the sequence of the BCR-ABL of the types of mutations that (for example non-patent document 1) a method for checking BCR-ABL substrate protein or of a method for detecting phosphorylation of CrkL immunoblotting (for example non-patent document 2) by, has been carried out.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
  • Inventor
  • OHBA Yusuke
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください

PAGE TOP

close
close
close
close
close
close